Medicenna Therapeutics Corp.
MDNA.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.20M | 1.32M | 919.30K | 1.59M | 1.31M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.66M | 4.05M | 2.95M | 2.97M | 3.51M |
| Operating Income | -3.66M | -4.05M | -2.95M | -2.97M | -3.51M |
| Income Before Tax | -3.71M | -3.05M | -2.66M | -10.31M | -3.66M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.71M | -3.05M | -2.66M | -10.31M | -3.66M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.71M | -3.05M | -2.66M | -10.31M | -3.66M |
| EBIT | -3.66M | -4.05M | -2.95M | -2.97M | -3.51M |
| EBITDA | -3.66M | -4.05M | -2.95M | -2.97M | -3.51M |
| EPS Basic | -0.05 | -0.04 | -0.04 | -0.15 | -0.05 |
| Normalized Basic EPS | -0.03 | -0.02 | -0.02 | -0.09 | -0.03 |
| EPS Diluted | -0.05 | -0.04 | -0.04 | -0.15 | -0.05 |
| Normalized Diluted EPS | -0.03 | -0.02 | -0.02 | -0.09 | -0.03 |
| Average Basic Shares Outstanding | 78.01M | 76.84M | 73.62M | 69.64M | 69.64M |
| Average Diluted Shares Outstanding | 78.01M | 76.84M | 73.62M | 69.64M | 69.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
